SBIR/STTR Research Award

Biodegradable Bone Graft Extender

Award identifier 4c69151c5e19339b27c175cbcd0cc3c32775570db1212ca19fdea977337f2dd8Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$0

Program and phase

SBIR · Phase I

Award year

2003

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
CAMBRIDGE SCIENTIFIC, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): In order to expand upon the clinical utility of bone replacement materials, Cambridge Scientific, Inc proposes to develop a biodegradable bone graft extender that has the ability to increase the working volume of autograft without compromising its inductive capacity of autograft Biodegradable extenders would be useful in situations in which autografts are preferable, yet the patient's own bone stocks are deficient. This grant application has as its goal the preclinical development of a degradable poly(propylene glycol-co-fumaric acid) ("PPF")-based bone graft extender containing osteoconductive hydroxylapatite fillers that can be mixed with osteoinductive cancellous autologous bone graft prior to implantation into a bony defect. In the Phase I SBIR feasibility project, Cambridge Scientific, Inc demonstrated in a small animal model that the addition of a PPF-based bone replacement material to autograft bone enhances osteointegratior of autograft which, in turn, has an effect on bony ingrowth. Following this demonstration of PPF/autograft enhancement of new bone formation, Cambridge Scientific, Inc will, in Phase II, evaluate the use of the extender material in a large animal (sheep) defect model to address the eventual clinical use of the extender in the reconstruction of significant skeletal defects. The development of new bone should couple to implant degradation in such a way that the structural integrity of the defect site is maintained throughout the recovery process Osteoinductive autograft material used in conjunction with an osteoconductive and mechanically stable resorbable scaffold would be attractive for both induction and expansion of new bone formation.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.